| 17beta-estradiol | multiple interactions | EXP | | 6480464 | [Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA | CTD | PMID:15072547 |
| 17beta-estradiol | decreases expression | EXP | | 6480464 | Estradiol results in decreased expression of ERBB2 mRNA | CTD | PMID:15072547 PMID:16393665 |
| 17beta-estradiol | increases expression | ISO | RGD:10533 | 6480464 | Estradiol results in increased expression of ERBB2 mRNA | CTD | PMID:17640349 |
| 17beta-estradiol | multiple interactions | ISO | RGD:10533 | 6480464 | [ERBB2 protein co-treated with ERBB3 protein] results in increased susceptibility to Estradiol | CTD | PMID:19861407 |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of ERBB2 mRNA | CTD | PMID:17555868 |
| 17beta-estradiol | decreases expression | EXP | | 6480464 | Estradiol results in decreased expression of ERBB2 protein | CTD | PMID:16488535 |
| 17beta-estradiol | decreases expression | EXP | | 6480464 | Estradiol results in decreased expression of ERBB2 mRNA | CTD | PMID:16393665 PMID:15072547 |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | Estradiol promotes the reaction [resveratrol results in increased expression of ERBB2 protein] | CTD | PMID:16488535 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ERBB2 mRNA | CTD | PMID:17555868 PMID:11162886 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of ERBB2 mRNA | CTD | PMID:22298810 PMID:22574217 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:2561 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ERBB2 mRNA | CTD | PMID:21215274 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of ERBB2 mRNA | CTD | PMID:22298810 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:10533 | 6480464 | Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ERBB2 promoter] | CTD | PMID:19654925 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ERBB2 mRNA | CTD | PMID:11162886 PMID:17555868 |
| 2-acetamidofluorene | increases expression | ISO | RGD:2561 | 6480464 | 2-Acetylaminofluorene results in increased expression of ERBB2 protein | CTD | PMID:11350689 |
| 3,3'-diindolylmethane | multiple interactions | EXP | | 6480464 | 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]; more ... | CTD | PMID:16580691 |
| 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol | decreases expression | EXP | | 6480464 | 1H,1H,2H,2H-perfluorodecanol results in decreased expression of ERBB2 mRNA | CTD | PMID:16393665 |
| 3H-1,2-dithiole-3-thione | increases expression | ISO | RGD:2561 | 6480464 | 1,2-dithiol-3-thione results in increased expression of ERBB2 mRNA | CTD | PMID:19162173 |
| 4'-epidoxorubicin | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen] | CTD | PMID:18768436 |
| 4'-epidoxorubicin | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] | CTD | PMID:16682728 PMID:16446318 |
| 4'-epidoxorubicin | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] | CTD | PMID:16446318 PMID:16682728 |
| 4-hydroxynon-2-enal | decreases expression | EXP | | 6480464 | 4-hydroxy-2-nonenal results in decreased expression of ERBB2 mRNA | CTD | PMID:12419474 |
| 4-nonylphenol | decreases expression | EXP | | 6480464 | 4-nonylphenol results in decreased expression of ERBB2 mRNA | CTD | PMID:16393665 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil]; more ... | CTD | PMID:21712253 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] | CTD | PMID:16446318 PMID:16682728 |
| 5-fluorouracil | affects expression | EXP | | 6480464 | Fluorouracil affects the expression of ERBB2 mRNA | CTD | PMID:15205334 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil] | CTD | PMID:15940066 |
| 5-fluorouracil | decreases response to substance | EXP | | 6480464 | ERBB2 results in decreased susceptibility to Fluorouracil | CTD | PMID:21712253 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] | CTD | PMID:16682728 PMID:16446318 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | CTD | PMID:9816327 |
| 5-fluorouracil | decreases response to substance | EXP | | 6480464 | ERBB2 mRNA results in decreased susceptibility to Fluorouracil | CTD | PMID:18337622 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | Curcumin promotes the reaction [Fluorouracil results in decreased phosphorylation of and results in decreased expression of and results in decreased activity of ERBB2 protein]; more ... | CTD | PMID:17918158 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with Fluorouracil] results in decreased expression of ERBB2 mRNA | CTD | PMID:15737843 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | [Apigenin co-treated with Fluorouracil] results in decreased expression of ERBB2 protein | CTD | PMID:19885610 |
| acetaldehyde | affects expression | ISO | RGD:10533 | 6480464 | Acetaldehyde affects the expression of ERBB2 mRNA | CTD | PMID:22634333 |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of ERBB2 mRNA; more ... | CTD | PMID:19424877 |
| acetylsalicylic acid | increases expression | EXP | | 6480464 | Aspirin results in increased expression of ERBB2 mRNA | CTD | PMID:20457246 |
| acrylamide | decreases phosphorylation | EXP | | 6480464 | Acrylamide analog results in decreased phosphorylation of ERBB2 protein | CTD | PMID:10753475 |
| afimoxifene | increases expression | ISO | RGD:10533 | 6480464 | 4-hydroxytamoxifen results in increased expression of ERBB2 mRNA | CTD | PMID:17640349 |
| afimoxifene | multiple interactions | EXP | | 6480464 | 4-hydroxytamoxifen inhibits the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]] | CTD | PMID:12439862 |
| afimoxifene | decreases response to substance | EXP | | 6480464 | ERBB2 results in decreased susceptibility to 4-hydroxytamoxifen | CTD | PMID:21233418 |
| afimoxifene | multiple interactions | EXP | | 6480464 | 4-hydroxytamoxifen inhibits the reaction [Estrogens results in decreased expression of ERBB2 mRNA] | CTD | PMID:21233418 |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of ERBB2 protein | CTD | PMID:16752155 |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of ERBB2 mRNA | CTD | PMID:21934132 |
| all-trans-retinoic acid | increases phosphorylation | ISO | RGD:10533 | 6480464 | Tretinoin results in increased phosphorylation of ERBB2 protein | CTD | PMID:16357442 |
| all-trans-retinoic acid | multiple interactions | ISO | RGD:10533 | 6480464 | HBEGF protein promotes the reaction [Tretinoin results in increased phosphorylation of ERBB2 protein] | CTD | PMID:16357442 |
| amiloride | decreases phosphorylation | EXP | | 6480464 | Amiloride results in decreased phosphorylation of ERBB2 protein | CTD | PMID:16059913 |
| ammonium chloride | affects expression | ISO | RGD:2561 | 6480464 | Ammonium Chloride affects the expression of ERBB2 mRNA | CTD | PMID:16483693 |
| apigenin | multiple interactions | EXP | | 6480464 | [Apigenin co-treated with Fluorouracil] results in decreased expression of ERBB2 protein | CTD | PMID:19885610 |
| benzo[a]pyrene | multiple interactions | ISO | RGD:10533 | 6480464 | Benzo(a)pyrene promotes the reaction [AHR protein binds to ERBB2 promoter] | CTD | PMID:19654925 |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of ERBB2 mRNA | CTD | PMID:16269432 PMID:22316170 |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of ERBB2 mRNA | CTD | PMID:22316170 |
| beta-hexachlorocyclohexane | increases activity | EXP | | 6480464 | beta-hexachlorocyclohexane results in increased activity of ERBB2 protein | CTD | PMID:11222871 |
| beta-hexachlorocyclohexane | multiple interactions | EXP | | 6480464 | 4-hydroxytamoxifen inhibits the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]]; more ... | CTD | PMID:12439862 |
| beta-hexachlorocyclohexane | increases activity | EXP | | 6480464 | beta-hexachlorocyclohexane results in increased activity of ERBB2 protein | CTD | PMID:11222871 PMID:9443065 |
| beta-hexachlorocyclohexane | increases expression | EXP | | 6480464 | beta-hexachlorocyclohexane results in increased expression of ERBB2 protein | CTD | PMID:12948864 |
| beta-hexachlorocyclohexane | increases expression | ISO | RGD:10533 | 6480464 | beta-hexachlorocyclohexane results in increased expression of ERBB2 mRNA | CTD | PMID:17640349 |
| bisphenol A | increases phosphorylation | ISO | RGD:10533 | 6480464 | bisphenol A results in increased phosphorylation of ERBB2 protein | CTD | PMID:21988766 |
| capsaicin | decreases expression | EXP | | 6480464 | Capsaicin results in decreased expression of ERBB2 protein | CTD | PMID:19855437 |
| capsaicin | affects expression | EXP | | 6480464 | Capsaicin affects the expression of ERBB2 mRNA | CTD | PMID:19502594 |
| carbamazepine | decreases expression | EXP | | 6480464 | Carbamazepine results in decreased expression of ERBB2 protein | CTD | PMID:16965676 |
| carbamazepine | affects expression | ISO | RGD:10533 | 6480464 | Carbamazepine affects the expression of ERBB2 mRNA | CTD | PMID:22634333 |
| carbamazepine | multiple interactions | EXP | | 6480464 | Carbamazepine results in increased degradation of and results in decreased expression of ERBB2 protein | CTD | PMID:17147113 |
| carbamazepine | decreases expression | EXP | | 6480464 | Carbamazepine results in decreased expression of ERBB2 mRNA | CTD | PMID:17147113 |
| carboplatin | multiple interactions | EXP | | 6480464 | ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] | CTD | PMID:16446318 |
| chloroquine | decreases expression | EXP | | 6480464 | Chloroquine results in decreased expression of ERBB2 protein | CTD | PMID:20332299 |
| chlorothalonil | increases activity | EXP | | 6480464 | tetrachloroisophthalonitrile results in increased activity of ERBB2 protein | CTD | PMID:11222871 |
| choline | multiple interactions | ISO | RGD:10533 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA | CTD | PMID:20938992 |
| cisplatin | multiple interactions | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin]; more ... | CTD | PMID:21712253 |
| cisplatin | affects response to substance | EXP | | 6480464 | ERBB2 protein affects the susceptibility to Cisplatin | CTD | PMID:10327070 |
| cisplatin | decreases response to substance | EXP | | 6480464 | ERBB2 results in decreased susceptibility to Cisplatin | CTD | PMID:21712253 |
| cisplatin | decreases response to substance | EXP | | 6480464 | ERBB2 mRNA results in decreased susceptibility to Cisplatin | CTD | PMID:18337622 |
| cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with Fluorouracil] results in decreased expression of ERBB2 mRNA | CTD | PMID:15737843 |
| cobalt dichloride | decreases expression | EXP | | 6480464 | cobaltous chloride results in decreased expression of ERBB2 mRNA | CTD | PMID:19376846 |
| copper(2+) sulfate | decreases expression | EXP | | 6480464 | Copper Sulfate results in decreased expression of ERBB2 mRNA | CTD | PMID:19549813 |
| coumestrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA | CTD | PMID:19167446 |
| curcumin | multiple interactions | EXP | | 6480464 | Curcumin promotes the reaction [Fluorouracil results in decreased phosphorylation of and results in decreased expression of and results in decreased activity of ERBB2 protein]; more ... | CTD | PMID:17918158 |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin analog results in decreased expression of ERBB2 protein; more ... | CTD | PMID:17041101 |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of ERBB2 protein; more ... | CTD | PMID:18719366 PMID:17041101 |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of ERBB2 mRNA; more ... | CTD | PMID:17041101 PMID:18719366 |
| cycloheximide | decreases expression | EXP | | 6480464 | Cycloheximide results in decreased expression of ERBB2 mRNA | CTD | PMID:15228094 PMID:15072547 |
| cycloheximide | decreases expression | EXP | | 6480464 | Cycloheximide results in decreased expression of ERBB2 mRNA | CTD | PMID:15072547 PMID:15228094 |
| cycloheximide | multiple interactions | EXP | | 6480464 | PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] | CTD | PMID:20379846 |
| cycloheximide | decreases expression | EXP | | 6480464 | Cycloheximide results in decreased expression of ERBB2 protein | CTD | PMID:20379846 |
| cycloheximide | multiple interactions | EXP | | 6480464 | [Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA | CTD | PMID:15072547 |
| cyclophosphamide | multiple interactions | EXP | | 6480464 | ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel] | CTD | PMID:17010609 |
| cyclophosphamide | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] | CTD | PMID:16682728 PMID:16446318 |
| cyclophosphamide | multiple interactions | EXP | | 6480464 | ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] | CTD | PMID:16446318 |
| cyclophosphamide | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] | CTD | PMID:16446318 PMID:16682728 |
| cyclophosphamide | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | CTD | PMID:9816327 |
| cyclophosphamide | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil] | CTD | PMID:15940066 |
| cyclophosphamide | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel] | CTD | PMID:15834928 |
| cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of ERBB2 mRNA | CTD | PMID:20106945 |
| DDT | increases phosphorylation | EXP | | 6480464 | DDT results in increased phosphorylation of ERBB2 protein | CTD | PMID:9070211 |
| dibenz[a,h]anthracene | decreases expression | EXP | | 6480464 | 1,2,5,6-dibenzanthracene results in decreased expression of ERBB2 mRNA | CTD | PMID:16269432 |
| dibutyl phthalate | increases expression | ISO | RGD:2561 | 6480464 | Dibutyl Phthalate results in increased expression of ERBB2 mRNA | CTD | PMID:17379624 |
| docetaxel anhydrous | multiple interactions | EXP | | 6480464 | ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel] | CTD | PMID:17010609 |
| docetaxel anhydrous | increases response to substance | EXP | | 6480464 | ERBB2 protein results in increased susceptibility to docetaxel | CTD | PMID:15567936 |
| docetaxel anhydrous | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel] | CTD | PMID:15834928 |
| doxorubicin | multiple interactions | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin]; more ... | CTD | PMID:21712253 |
| doxorubicin | increases expression | ISO | RGD:2561 | 6480464 | Doxorubicin results in increased expression of ERBB2 protein | CTD | PMID:17308081 |
| doxorubicin | multiple interactions | ISO | RGD:2561 | 6480464 | ERBB2 protein promotes the reaction [NRG1 protein inhibits the reaction [Doxorubicin results in decreased expression of TNNI3 protein]]; more ... | CTD | PMID:19801490 |
| doxorubicin | multiple interactions | ISO | RGD:2561 | 6480464 | Doxorubicin promotes the reaction [HSP90AA1 protein binds to ERBB2 protein] | CTD | PMID:17308081 |
| doxorubicin | multiple interactions | ISO | RGD:10533 | 6480464 | NRG1 protein affects the reaction [Doxorubicin affects the phosphorylation of ERBB2 protein] | CTD | PMID:15833803 |
| doxorubicin | multiple interactions | EXP | | 6480464 | [TOP2A protein co-treated with ERBB2 protein] results in increased susceptibility to Doxorubicin | CTD | PMID:15486187 |
| doxorubicin | decreases response to substance | EXP | | 6480464 | ERBB2 results in decreased susceptibility to Doxorubicin | CTD | PMID:21712253 |
| doxorubicin | multiple interactions | EXP | | 6480464 | ERBB2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of AKT1 protein] | CTD | PMID:16168102 |
| doxorubicin | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | CTD | PMID:9816327 |
| doxorubicin | affects response to substance | EXP | | 6480464 | ERBB2 protein affects the susceptibility to Doxorubicin | CTD | PMID:10327070 |
| doxorubicin | multiple interactions | EXP | | 6480464 | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel] | CTD | PMID:15834928 |
| doxorubicin | multiple interactions | EXP | | 6480464 | ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel] | CTD | PMID:17010609 |
| doxorubicin | affects expression | EXP | | 6480464 | Doxorubicin affects the expression of ERBB2 mRNA | CTD | PMID:15205334 |
| elemental selenium | increases expression | EXP | | 6480464 | Selenium results in increased expression of ERBB2 mRNA | CTD | PMID:19244175 |
| elemental selenium | multiple interactions | EXP | | 6480464 | [Selenium co-treated with Vitamin E] results in increased expression of ERBB2 mRNA | CTD | PMID:19244175 |
| etoposide | multiple interactions | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; more ... | CTD | PMID:21712253 |
| etoposide | decreases expression | EXP | | 6480464 | Etoposide results in decreased expression of ERBB2 mRNA | CTD | PMID:15228094 |
| etoposide | decreases response to substance | EXP | | 6480464 | ERBB2 results in decreased susceptibility to Etoposide | CTD | PMID:21712253 |
| etoposide | affects response to substance | EXP | | 6480464 | ERBB2 protein affects the susceptibility to Etoposide | CTD | PMID:10327070 |
| folic acid | multiple interactions | ISO | RGD:10533 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA | CTD | PMID:20938992 |
| fulvestrant | increases expression | EXP | | 6480464 | fulvestrant results in increased expression of ERBB2 mRNA | CTD | PMID:15072547 |
| gefitinib | multiple interactions | EXP | | 6480464 | gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; more ... | CTD | PMID:17898861 |
| gefitinib | decreases phosphorylation | EXP | | 6480464 | gefitinib results in decreased phosphorylation of ERBB2 protein | CTD | PMID:16243822 |
| geldanamycin | multiple interactions | EXP | | 6480464 | [geldanamycin binds to HSP90B1 protein] inhibits the reaction [HSP90B1 protein binds to ERBB2 protein] | CTD | PMID:8617772 |
| geldanamycin | increases degradation | EXP | | 6480464 | geldanamycin results in increased degradation of ERBB2 protein | CTD | PMID:11071886 more ... |
| geldanamycin | increases degradation | EXP | | 6480464 | geldanamycin results in increased degradation of ERBB2 protein | CTD | PMID:17959518 more ... |
| geldanamycin | increases degradation | EXP | | 6480464 | geldanamycin results in increased degradation of ERBB2 protein | CTD | PMID:17959518 more ... |
| geldanamycin | increases degradation | EXP | | 6480464 | geldanamycin results in increased degradation of ERBB2 protein | CTD | PMID:8617772 more ... |
| geldanamycin | increases degradation | EXP | | 6480464 | geldanamycin results in increased degradation of ERBB2 protein | CTD | PMID:11071886 more ... |
| hydrogen peroxide | affects expression | EXP | | 6480464 | Hydrogen Peroxide affects the expression of ERBB2 mRNA | CTD | PMID:20044591 |
| hydrogen peroxide | decreases expression | EXP | | 6480464 | Hydrogen Peroxide results in decreased expression of ERBB2 mRNA | CTD | PMID:12419474 |
| L-methionine | multiple interactions | ISO | RGD:10533 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA | CTD | PMID:20938992 |
| lead(0) | decreases expression | EXP | | 6480464 | Lead results in decreased expression of ERBB2 mRNA | CTD | PMID:19921347 |
| LY294002 | multiple interactions | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin]; more ... | CTD | PMID:21712253 |
| LY294002 | multiple interactions | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]] | CTD | PMID:12439862 |
| mechlorethamine | decreases expression | EXP | | 6480464 | Mechlorethamine results in decreased expression of ERBB2 protein | CTD | PMID:17932452 |
| mercaptopurine | decreases expression | ISO | RGD:2561 | 6480464 | 6-Mercaptopurine results in decreased expression of ERBB2 mRNA | CTD | PMID:23358152 |
| methotrexate | affects response to substance | EXP | | 6480464 | ERBB2 protein affects the susceptibility to Methotrexate | CTD | PMID:10327070 |
| mitoxantrone | multiple interactions | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone]; more ... | CTD | PMID:21712253 |
| mitoxantrone | decreases response to substance | EXP | | 6480464 | ERBB2 results in decreased susceptibility to Mitoxantrone | CTD | PMID:21712253 |
| N-ethyl-N-nitrosourea | increases mutagenesis | ISO | RGD:2561 | 6480464 | Ethylnitrosourea results in increased mutagenesis of ERBB2 gene | CTD | PMID:16651423 |
| N-methyl-N'-nitro-N-nitrosoguanidine | increases expression | EXP | | 6480464 | Methylnitronitrosoguanidine results in increased expression of ERBB2 mRNA | CTD | PMID:12634122 |
| paclitaxel | multiple interactions | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel]; more ... | CTD | PMID:21712253 |
| paclitaxel | affects response to substance | EXP | | 6480464 | ERBB2 protein affects the susceptibility to Paclitaxel | CTD | PMID:10327070 |
| paclitaxel | decreases response to substance | EXP | | 6480464 | ERBB2 results in decreased susceptibility to Paclitaxel | CTD | PMID:21712253 |
| paclitaxel | multiple interactions | EXP | | 6480464 | 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein] | CTD | PMID:16580691 |
| paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of ERBB2 mRNA | CTD | PMID:21420995 |
| perfluorooctane-1-sulfonic acid | decreases expression | ISO | RGD:2561 | 6480464 | perfluorooctane sulfonic acid results in decreased expression of ERBB2 mRNA | CTD | PMID:18692542 |
| permethrin | increases activity | EXP | | 6480464 | Permethrin results in increased activity of ERBB2 protein | CTD | PMID:11222871 |
| phorbol 13-acetate 12-myristate | multiple interactions | EXP | | 6480464 | PIN1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of ERBB2 protein] | CTD | PMID:20479004 |
| phorbol 13-acetate 12-myristate | increases expression | EXP | | 6480464 | Tetradecanoylphorbol Acetate results in increased expression of ERBB2 protein | CTD | PMID:20479004 |
| purine-6-thiol | decreases expression | ISO | RGD:2561 | 6480464 | 6-Mercaptopurine results in decreased expression of ERBB2 mRNA | CTD | PMID:23358152 |
| quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of ERBB2 protein | CTD | PMID:15741050 |
| quercetin | increases expression | EXP | | 6480464 | Quercetin results in increased expression of ERBB2 mRNA | CTD | PMID:14715546 |
| raloxifene | decreases response to substance | ISO | RGD:10533 | 6480464 | ERBB2 protein results in decreased susceptibility to Raloxifene | CTD | PMID:16609042 |
| reserpine | increases response to substance | ISO | RGD:2561 | 6480464 | ERBB2 protein results in increased susceptibility to Reserpine | CTD | PMID:8093862 |
| resveratrol | multiple interactions | EXP | | 6480464 | Estradiol promotes the reaction [resveratrol results in increased expression of ERBB2 protein] | CTD | PMID:16488535 |
| resveratrol | decreases phosphorylation | EXP | | 6480464 | resveratrol results in decreased phosphorylation of ERBB2 protein | CTD | PMID:20729295 |
| resveratrol | multiple interactions | EXP | | 6480464 | EGF protein inhibits the reaction [resveratrol results in decreased phosphorylation of ERBB2 protein] | CTD | PMID:20729295 |
| resveratrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA | CTD | PMID:19167446 |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of ERBB2 protein | CTD | PMID:16488535 |
| resveratrol | decreases expression | ISO | RGD:10533 | 6480464 | resveratrol results in decreased expression of ERBB2 | CTD | PMID:15688416 |
| resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of ERBB2 protein; more ... | CTD | PMID:16488535 |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of ERBB2 | CTD | PMID:15688416 |
| romidepsin | decreases expression | EXP | | 6480464 | romidepsin results in decreased expression of ERBB2 protein | CTD | PMID:15014036 |
| selenium atom | multiple interactions | EXP | | 6480464 | [Selenium co-treated with Vitamin E] results in increased expression of ERBB2 mRNA | CTD | PMID:19244175 |
| selenium atom | increases expression | EXP | | 6480464 | Selenium results in increased expression of ERBB2 mRNA | CTD | PMID:19244175 |
| tamoxifen | multiple interactions | EXP | | 6480464 | ERBB2 protein inhibits the reaction [PA2G4 protein results in increased susceptibility to Tamoxifen] | CTD | PMID:20379846 |
| tamoxifen | decreases response to substance | EXP | | 6480464 | ERBB2 protein results in decreased susceptibility to Tamoxifen | CTD | PMID:15665275 more ... |
| tamoxifen | decreases response to substance | EXP | | 6480464 | ERBB2 protein results in decreased susceptibility to Tamoxifen | CTD | PMID:16023854 more ... |
| tamoxifen | increases phosphorylation | EXP | | 6480464 | Tamoxifen results in increased phosphorylation of ERBB2 protein | CTD | PMID:17157789 |
| tamoxifen | decreases response to substance | EXP | | 6480464 | ERBB2 protein results in decreased susceptibility to Tamoxifen | CTD | PMID:16023854 more ... |
| tamoxifen | decreases response to substance | EXP | | 6480464 | ERBB2 protein results in decreased susceptibility to Tamoxifen | CTD | PMID:15665275 more ... |
| tamoxifen | decreases response to substance | EXP | | 6480464 | ERBB2 protein results in decreased susceptibility to Tamoxifen | CTD | PMID:15665275 more ... |
| tamoxifen | increases phosphorylation | ISO | RGD:10533 | 6480464 | Tamoxifen results in increased phosphorylation of ERBB2 protein | CTD | PMID:21138602 |
| tamoxifen | increases expression | ISO | RGD:10533 | 6480464 | Tamoxifen results in increased expression of ERBB2 protein | CTD | PMID:21138602 |
| tamoxifen | multiple interactions | EXP | | 6480464 | [ERBB2 protein results in increased activity of ESR1 protein] which results in decreased susceptibility to Tamoxifen | CTD | PMID:20179226 |
| tamoxifen | decreases response to substance | EXP | | 6480464 | ERBB2 protein results in decreased susceptibility to Tamoxifen | CTD | PMID:16023854 more ... |
| tert-butyl hydroperoxide | decreases expression | EXP | | 6480464 | tert-Butylhydroperoxide results in decreased expression of ERBB2 mRNA | CTD | PMID:15336504 |
| tetraphene | decreases expression | EXP | | 6480464 | benz(a)anthracene results in decreased expression of ERBB2 mRNA | CTD | PMID:21635667 |
| trans-resveratrol | multiple interactions | EXP | | 6480464 | Estradiol promotes the reaction [resveratrol results in increased expression of ERBB2 protein] | CTD | PMID:16488535 |
| trans-resveratrol | decreases phosphorylation | EXP | | 6480464 | resveratrol results in decreased phosphorylation of ERBB2 protein | CTD | PMID:20729295 |
| trans-resveratrol | multiple interactions | EXP | | 6480464 | EGF protein inhibits the reaction [resveratrol results in decreased phosphorylation of ERBB2 protein] | CTD | PMID:20729295 |
| trans-resveratrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA | CTD | PMID:19167446 |
| trans-resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of ERBB2 protein | CTD | PMID:16488535 |
| trans-resveratrol | decreases expression | ISO | RGD:10533 | 6480464 | resveratrol results in decreased expression of ERBB2 | CTD | PMID:15688416 |
| trans-resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of ERBB2 protein; more ... | CTD | PMID:16488535 |
| trans-resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of ERBB2 | CTD | PMID:15688416 |
| trichloroethene | decreases expression | ISO | RGD:10533 | 6480464 | Trichloroethylene results in decreased expression of ERBB2 mRNA | CTD | PMID:15363585 |
| trimellitic anhydride | decreases expression | ISO | RGD:10533 | 6480464 | trimellitic anhydride results in decreased expression of ERBB2 mRNA | CTD | PMID:19042947 |
| undecane | decreases expression | ISO | RGD:2561 | 6480464 | undecane results in decreased expression of ERBB2 protein | CTD | PMID:17337753 |
| vincaleukoblastine | affects response to substance | EXP | | 6480464 | ERBB2 protein affects the susceptibility to Vinblastine | CTD | PMID:10327070 |
| vincristine | increases response to substance | EXP | | 6480464 | ERBB2 gene SNP results in increased susceptibility to Vincristine | CTD | PMID:20864405 |